Get the Stockscreener App
25.52
0.53%
0.09
Immunome Inc stock is traded at $25.52, with a volume of 408.25K.
It is up +0.53% in the last 24 hours and up +17.76% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$25.43
Open:
$25.45
24h Volume:
408.25K
Relative Volume:
0.20
Market Cap:
$2.82B
Revenue:
$12.59M
Net Income/Loss:
$-212.39M
P/E Ratio:
-8.2715
EPS:
-3.0853
Net Cash Flow:
$-185.92M
1W Performance:
+7.06%
1M Performance:
+17.76%
6M Performance:
+135.19%
1Y Performance:
+163.83%
1-Day Range:
$24.91
$25.97
1-Week Range:
$23.51
$26.62
52-Week Range:
$5.1501
$26.62
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
25.55 | 2.81B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.72 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.86 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.45 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.59 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.21 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Trading Recap: How do insiders feel about Immunome Inc2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Institutional Investors Are Immunome, Inc.'s (NASDAQ:IMNM) Biggest Bettors and Were Rewarded After Last Week's US$382m Market Cap Gain - 富途牛牛
Technical Analysis: Is TSHA part of any major indexTrade Analysis Report & Weekly Stock Performance Updates - baoquankhu1.vn
What are Immunome Incs recent SEC filings showingJuly 2025 Market Mood & Breakout Confirmation Trade Signals - baoquankhu1.vn
Immunome stock reaches 52-week high at $25.32 By Investing.com - Investing.com Australia
(IMNM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunome (NASDAQ:IMNM) Hits New 12-Month HighWhat's Next? - MarketBeat
Immunome stock reaches 52-week high at $25.32 - Investing.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM) - The Globe and Mail
Nasdaq Moves: What is the long term forecast for Immunome Inc stockJuly 2025 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Sentiment Recap: Is Immunome Inc a good stock for dollar cost averaging2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA PlanWhat's Changed - simplywall.st
Bond Watch: Does Immunome Inc have declining or rising EPSEarnings Growth Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Immunome, Inc. (IMNM) Stock Analysis: A Promising Upside of Nearly 51% as Analysts Show Strong Support - DirectorsTalk Interviews
Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat SuccessHas The Bull Case Changed? - Yahoo Finance
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance
Immunome, Inc. $IMNM Holdings Boosted by Nisa Investment Advisors LLC - MarketBeat
Is Immunome Inc affected by consumer sentiment2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IMNM with $31 Price Tar - GuruFocus
Immunome (NASDAQ:IMNM) Trading 8.1% HigherHere's Why - MarketBeat
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Insider Monkey
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush - MarketBeat
Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation - Sahm
Returns Recap: Does Immunome Inc have declining or rising EPSWeekly Trade Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Responsive Playbooks and the IMNM Inflection - Stock Traders Daily
Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms - TechStock²
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Insider Monkey
Is Immunome Inc. stock supported by strong fundamentalsMarket Rumors and News & Affordable Market Investment - Улправда
Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" - Finviz
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Franklin Credit Management CorporationImmunome to Present at 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update - TechStock²
Immunome’s Stock Under the Microscope: Can IMNM Turn Recent Volatility Into a Breakout? - AD HOC NEWS
Immunome (NASDAQ:IMNM) Shares Down 7%Time to Sell? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Decliners Report: Can Immunome Inc stock deliver strong Q4 earningsJuly 2025 Outlook & Weekly High Return Opportunities - Bộ Nội Vụ
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer? - MSN
Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily
Immunome (IMNM) CEO Siegall buys $100k in shares By Investing.com - Investing.com South Africa
Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks
Insider Buying: Clay Siegall Acquires Additional Shares of Immun - GuruFocus
Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat
Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
2.26%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):